Drugs / Suranix
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT01747642 Comparator | Dec 2012 → Dec 2013 | — | Clinical Research Organization, Dhaka, Bangladesh | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Suranix | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01747642 ↗ |
| Route | Oral | “Tab Suranix 200 mg 2 tab bd and Syp Oncoxin 25 ml bd and Cap. Oncoxin bd for 180 days” NCT01747642 ↗ |